MRSN - Mersana Therapeutics Stock Price, News & Analysis

$18.78 0.24 (1.29 %)
(As of 11/24/2017 04:00 PM ET)
Previous Close$18.54
Today's Range$18.00 - $19.71
52-Week Range$12.71 - $21.01
Volume35,400 shs
Average Volume68,683 shs
Market Capitalization$427.31 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Mersana Therapeutics (NASDAQ:MRSN)

Mersana Therapeutics logoMersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRSN
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio5.58%
Quick Ratio5.58%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.68 per share
Price / Book5.10

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees68
Outstanding Shares22,750,000

Frequently Asked Questions for Mersana Therapeutics (NASDAQ:MRSN)

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) issued its earnings results on Thursday, November, 9th. The company reported ($0.35) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.49) by $0.14. The company had revenue of $6.27 million for the quarter, compared to the consensus estimate of $3.93 million. View Mersana Therapeutics' Earnings History.

Where is Mersana Therapeutics' stock going? Where will Mersana Therapeutics' stock price be in 2017?

4 brokerages have issued 1 year price objectives for Mersana Therapeutics' stock. Their predictions range from $23.00 to $25.00. On average, they anticipate Mersana Therapeutics' share price to reach $23.67 in the next year. View Analyst Ratings for Mersana Therapeutics.

Who are some of Mersana Therapeutics' key competitors?

Who are Mersana Therapeutics' key executives?

Mersana Therapeutics' management team includes the folowing people:

  • David M. Mott, Chairman of the Board (Age 51)
  • Anna Protopapas, President, Chief Executive Officer, Director (Age 52)
  • Timothy B. Lowinger Ph.D., Chief Scientific Officer
  • Wayne Foster CPA, Vice President - Finance
  • Donald A. Bergstrom M.D. Ph.D., Chief Medical Officer
  • Lawrence M. Alleva, Independent Director (Age 67)

When did Mersana Therapeutics IPO?

(MRSN) raised $75 million in an initial public offering on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who owns Mersana Therapeutics stock?

Mersana Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (1.48%), Allianz Asset Management GmbH (0.36%), DekaBank Deutsche Girozentrale (0.13%), Bank of New York Mellon Corp (0.06%) and California State Teachers Retirement System (0.04%). View Institutional Ownership Trends for Mersana Therapeutics.

Who sold Mersana Therapeutics stock? Who is selling Mersana Therapeutics stock?

Mersana Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale and JPMorgan Chase & Co.. View Insider Buying and Selling for Mersana Therapeutics.

Who bought Mersana Therapeutics stock? Who is buying Mersana Therapeutics stock?

Mersana Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Bank of New York Mellon Corp and California State Teachers Retirement System. View Insider Buying and Selling for Mersana Therapeutics.

How do I buy Mersana Therapeutics stock?

Shares of Mersana Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mersana Therapeutics' stock price today?

One share of Mersana Therapeutics stock can currently be purchased for approximately $18.78.

How big of a company is Mersana Therapeutics?

Mersana Therapeutics has a market capitalization of $427.31 million. Mersana Therapeutics employs 68 workers across the globe.

How can I contact Mersana Therapeutics?

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]


MarketBeat Community Rating for Mersana Therapeutics (MRSN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  38 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  76
MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Mersana Therapeutics (NASDAQ:MRSN)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuySell
Consensus Rating Score: 3.003.003.000.00
Ratings Breakdown: 0 Sell Ratings
0 Hold Ratings
4 Buy Ratings
0 Strong Buy Ratings
0 Sell Ratings
0 Hold Ratings
4 Buy Ratings
0 Strong Buy Ratings
0 Sell Ratings
0 Hold Ratings
4 Buy Ratings
0 Strong Buy Ratings
0 Sell Ratings
0 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings
Consensus Price Target: $23.67$23.67$23.67$0.00
Price Target Upside: 68.45% upside68.45% upside68.45% upside0.00% downside

Consensus Price Target History for Mersana Therapeutics (NASDAQ:MRSN)

Price Target History for Mersana Therapeutics (NASDAQ:MRSN)

Analysts' Ratings History for Mersana Therapeutics (NASDAQ:MRSN)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/24/2017WedbushReiterated RatingOutperform -> Outperform$25.00HighView Rating Details
7/24/2017Leerink SwannInitiated CoverageOutperform -> Outperform$23.00HighView Rating Details
7/24/2017J P Morgan Chase & CoInitiated CoverageOverweight -> Overweight$23.00HighView Rating Details
7/24/2017Cowen IncInitiated CoverageOutperformHighView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Mersana Therapeutics (NASDAQ:MRSN)

Earnings by Quarter for Mersana Therapeutics (NASDAQ:MRSN)

Earnings History by Quarter for Mersana Therapeutics (NASDAQ MRSN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.49)($0.35)$3.93 million$6.27 millionViewN/AView Earnings Details
8/11/2017Q2 2017($0.56)($6.33)$3.33 million$3.73 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Mersana Therapeutics (NASDAQ:MRSN)
2017 EPS Consensus Estimate: ($1.52)
2018 EPS Consensus Estimate: ($8.72)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20172($0.58)($0.50)($0.54)
Q3 20172($0.51)($0.43)($0.47)
Q4 20172($0.56)($0.46)($0.51)
Q1 20181($2.33)($2.33)($2.33)
Q2 20181($2.26)($2.26)($2.26)
Q3 20181($2.46)($2.46)($2.46)
Q4 20181($1.67)($1.67)($1.67)
Q1 20191$9.82$9.82$9.82
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Mersana Therapeutics (NASDAQ:MRSN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Mersana Therapeutics (NASDAQ MRSN)

Institutional Ownership Percentage: 76.43%
Insider Trades by Quarter for Mersana Therapeutics (NASDAQ:MRSN)
Insider Trades by Quarter for Mersana Therapeutics (NASDAQ:MRSN)

Insider Trades by Quarter for Mersana Therapeutics (NASDAQ MRSN)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/3/2017M James BarrettMajor ShareholderBuy1,000,000$15.00$15,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Mersana Therapeutics (NASDAQ MRSN)

Source:
DateHeadline
Mersana Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MRSN-US : November 22, 2017Mersana Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MRSN-US : November 22, 2017
finance.yahoo.com - November 23 at 6:37 AM
Mersana Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MRSN-US : November 9, 2017Mersana Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MRSN-US : November 9, 2017
finance.yahoo.com - November 12 at 8:37 AM
Mersana Announces Third Quarter 2017 Financial Results and Provides Business UpdatesMersana Announces Third Quarter 2017 Financial Results and Provides Business Updates
finance.yahoo.com - November 12 at 8:37 AM
 Mersana Therapeutics, Inc. (MRSN) Receives Consensus Recommendation of "Strong Buy" from Analysts Mersana Therapeutics, Inc. (MRSN) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - November 11 at 11:46 PM
Mersana Therapeutics, Inc. (MRSN) Announces Quarterly  Earnings Results, Beats Expectations By $0.13 EPSMersana Therapeutics, Inc. (MRSN) Announces Quarterly Earnings Results, Beats Expectations By $0.13 EPS
www.americanbankingnews.com - November 10 at 2:56 PM
Zacks: Mersana Therapeutics, Inc. (MRSN) Receives Average Rating of "Strong Buy" from AnalystsZacks: Mersana Therapeutics, Inc. (MRSN) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - November 7 at 10:59 AM
A requirement at this Cambridge biotech: Must love dogsA requirement at this Cambridge biotech: Must love dogs
finance.yahoo.com - November 2 at 6:34 AM
Mersana Therapeutics Presents New Data on XMT-1536, a NaPi2b Targeting Antibody Drug Conjugate, at the AACR-NCI-EORTC International ConferenceMersana Therapeutics Presents New Data on XMT-1536, a NaPi2b Targeting Antibody Drug Conjugate, at the AACR-NCI-EORTC International Conference
finance.yahoo.com - October 31 at 6:30 AM
Mersana Announces FDA Clearance of IND Application for XMT-1536, a First-in-Class Antibody Drug Conjugate Targeting NaPi2bMersana Announces FDA Clearance of IND Application for XMT-1536, a First-in-Class Antibody Drug Conjugate Targeting NaPi2b
finance.yahoo.com - October 31 at 6:30 AM
Mersana Therapeutics Announces Poster Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsMersana Therapeutics Announces Poster Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
finance.yahoo.com - October 24 at 6:53 AM
 Mersana Therapeutics, Inc. (MRSN) Given $23.67 Average Target Price by Brokerages Mersana Therapeutics, Inc. (MRSN) Given $23.67 Average Target Price by Brokerages
www.americanbankingnews.com - October 23 at 10:58 AM
Mersana Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MRSN-US : October 16, 2017Mersana Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MRSN-US : October 16, 2017
finance.yahoo.com - October 17 at 12:17 AM
Boston biotech developing obesity drug pulls down $120M in IPOBoston biotech developing obesity drug pulls down $120M in IPO
finance.yahoo.com - October 5 at 9:17 AM
Mersana Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MRSN-US : September 20, 2017Mersana Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MRSN-US : September 20, 2017
finance.yahoo.com - September 22 at 6:07 AM
Mersana Therapeutics, Inc. – Value Analysis (NASDAQ:MRSN) : September 21, 2017Mersana Therapeutics, Inc. – Value Analysis (NASDAQ:MRSN) : September 21, 2017
finance.yahoo.com - September 22 at 6:07 AM
 Mersana Therapeutics, Inc. (MRSN) Given $23.67 Consensus Target Price by Brokerages Mersana Therapeutics, Inc. (MRSN) Given $23.67 Consensus Target Price by Brokerages
www.americanbankingnews.com - September 7 at 4:44 AM
Mersana Therapeutics to Participate in Investor Conferences in SeptemberMersana Therapeutics to Participate in Investor Conferences in September
finance.yahoo.com - August 31 at 7:30 AM
 Mersana Therpts (MRSN) Given Consensus Recommendation of "" by Analysts Mersana Therpts (MRSN) Given Consensus Recommendation of "" by Analysts
www.americanbankingnews.com - August 17 at 12:38 PM
FY2017 EPS Estimates for Mersana Therpts (MRSN) Decreased by Leerink SwannFY2017 EPS Estimates for Mersana Therpts (MRSN) Decreased by Leerink Swann
www.americanbankingnews.com - August 17 at 9:00 AM
FY2018 Earnings Forecast for MERSANA THERPTS (MRSN) Issued By Leerink SwannFY2018 Earnings Forecast for MERSANA THERPTS (MRSN) Issued By Leerink Swann
www.americanbankingnews.com - August 16 at 1:32 PM
Mersana Therpts (NASDAQ:MRSN) Short Interest Down 95.9% in JulyMersana Therpts (NASDAQ:MRSN) Short Interest Down 95.9% in July
www.americanbankingnews.com - August 13 at 2:20 AM
Mersana Therpts (MRSN) Issues  Earnings Results, Misses Expectations By $5.77 EPSMersana Therpts (MRSN) Issues Earnings Results, Misses Expectations By $5.77 EPS
www.americanbankingnews.com - August 12 at 10:41 AM
Mersana Announces Second Quarter 2017 Financial Results and Provides Business UpdatesMersana Announces Second Quarter 2017 Financial Results and Provides Business Updates
finance.yahoo.com - August 12 at 5:53 AM
Mersana Therapeutics to Present at Wedbush PacGrow Healthcare ConferenceMersana Therapeutics to Present at Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 10 at 6:03 AM
Mersana Therpts (NASDAQ:MRSN) Quiet Period Set To Expire  on August 7thMersana Therpts' (NASDAQ:MRSN) Quiet Period Set To Expire on August 7th
www.americanbankingnews.com - August 2 at 7:04 AM
-$0.56 Earnings Per Share Expected for Mersana Therpts (MRSN) This Quarter-$0.56 Earnings Per Share Expected for Mersana Therpts (MRSN) This Quarter
www.americanbankingnews.com - August 1 at 12:16 AM
Mersana Therpts Expected to Post Q2 2017 Earnings of ($0.58) Per Share (NASDAQ:MRSN)Mersana Therpts Expected to Post Q2 2017 Earnings of ($0.58) Per Share (NASDAQ:MRSN)
www.americanbankingnews.com - July 26 at 8:40 AM
Brokers Set Expectations for Mersana Therpts Q2 2017 Earnings (MRSN)Brokers Set Expectations for Mersana Therpts' Q2 2017 Earnings (MRSN)
www.americanbankingnews.com - July 26 at 8:40 AM
Mersana Therpts (NASDAQ:MRSN) Earns "Outperform" Rating from WedbushMersana Therpts (NASDAQ:MRSN) Earns "Outperform" Rating from Wedbush
www.americanbankingnews.com - July 24 at 9:32 AM
M James Barrett Acquires 1,000,000 Shares of Mersana Therapeutics Inc (NASDAQ:MRSN) StockM James Barrett Acquires 1,000,000 Shares of Mersana Therapeutics Inc (NASDAQ:MRSN) Stock
www.americanbankingnews.com - July 6 at 7:22 PM

Social Media

Financials

Chart

Mersana Therapeutics (NASDAQ MRSN) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.